Frank Hensel

Frank holds a PH.D. in biology from the University of Würzburg. After his Post-Doc-position he became CEO and Co-Founder of the start-up company OncoMab GmbH developing natural human monoclonal antibodies for cancer treatment. Frank led different partnering activities and participated in the development of the lead antibody into the clinic. After the Merger of OncoMab with a US-based company the joint company Patrys Ltd. went public at the Australian Stock Exchange in 2007.

Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio four companies already entered the clinical stage and one company, Amal Therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to € 425m.